5‐fluorouracil‐induced bradycardia: A case report


  • Worachaya Pengthina Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, 90100, Thailand
  • Chirawadee Sathitruangsak Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand
  • Ingporn Jiamset Oncology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, 90110, Thailand
  • Warunsuda Sripakdee Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, 90100, Thailand


5-Fluorouracil, antimetabolite, chemotherapy, cardiotoxicity, bradycardia


Background and Objective: Cardiotoxicity is one of the adverse effects associated with 5-fluorouracil (5-FU) based regimen. Diverse abnormal clinical manifestations such as angina, palpitation, dyspnea, myocardial infarction, cardiogenic shock and cardiac arrest have been linked to 5-FU. Although asymptomatic electrocardiogram (ECG) abnormalities were presented, the identify of bradycardia was rarely reported. This case report aimed to describe the case of asymptomatic bradycardia after receiving 5-FU treatment.

Case presentation: We report a case of 47-year-old female who was previously diagnosed with mucinous adenocarcinoma of cervix clinical stage IVB 9 months and had a history of structural heart disease. Her cardiac condition, which was investigated before chemotherapy treatment, showed stable disease. However, during 5-FU palliative chemotherapy (Cycle 1), she developed asymptomatic bradycardia on the third day of cycle with 5-FU 1000 mg/m2. After occurrence of the cardiac event, 5-FU was discontinued, and reintroduction of 5-FU was not performed.

Conclusion: 5-FU induced bradycardia is an unusual cardiac event. In patients with history of cardiovascular disease, evaluating cardiac disease and cardiovascular risks should be performed before treatment initiation. Moreover, close monitoring with ECG or a 12-leads Holter monitoring are necessary as well. 5-FU should be immediate discontinued after the event is suspected. Reintroduction of 5-FU could be performed in some patients without serious problems. However, risk-benefit assessment should be done before performing rechallenge therapy.


Jurczyk M, Król M, Midro A, Kurnik-Łucka M, Poniatowski A, Gil K. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J Clin Med 2021;10(19).

Lee AD, McKay MJ. Symptomaitc 5-fluorouracil-induced sinus bradycardia. Intern Med J 2011;41(7):566-70.

Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17(4):729-36.

Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy-a survey of 427 patients. Med Sci Monit 2002;8(6):PI51-7.

Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003;65(2):108-12.

Talapatra K, Rajesh I, Rajesh B, Selvamani B, Subhashini J. Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Cancer Res Ther 2007;3(3):169-71.

Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134(1):75-82.

Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010;40(4):303-7.

Khan MA, Masood N, Husain N, Ahmad B, Aziz T, Naeem A. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc 2012;62(5):430-4.

Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol 2014;25(5):1059-64.

Hafeez I, Lone AA, Beig J, Alai M, Dar M, Tramboo N. Effect of 5-fluorouracil on sinoatrial node and conduction system of heart. J Adv Med Med Res 2017;4:184.

Peng J, Dong C, Wang C, Li W, Yu H, Zhang M, et al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun (Lond) 2018;38(1):22.

Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman JJM, Frödin JE, et al. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open 2022;7(3):100427.

Lestuzzi C, Tartuferi L, Viel E, Buonadonna A, Vaccher E, Berretta M. Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. Oncologist 2020;25(8):e1254.

Jin X, Bai Y, Gao L, Wu S. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. Cancer Chemother Pharmacol 2019;84(3):599-607.

Jensen SA, Hasbak P, Mortensen J, Sørensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010;28(36):5280-6.

Yuan C, Parekh H, Allergra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardiooncology 2019;5:13.

Kanduri J, More LA, Godishala A, Asnani A. Fluorouracil-Associated Cardiotoxicity. Cardiol Clin 2019;37(4):399-405.

Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and ancrdiotoxicity: a review. Ther Adr Med Oncol 2018;10.

Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Curr Oncol Rep 2016;18(6):35.

Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58(4):487-93.

Tsavaris N, Kosmas C, Vadiaka M, Skopelitis E, Kopterides P, Pamouki S, et al. 5-Fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: A prospective study. J BUON 2005;10:205-11.

Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol 2017;8(6):970-9.

Redman JM, Rhea L, Brofferio A, Whelpley M, Gulley JL, Gatti-Mays ME, et al. Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. J Gastrointest Oncol 2019;10(5):1010-4.




How to Cite

Pengthina W, Sathitruangsak C, Jiamset I, Sripakdee W. 5‐fluorouracil‐induced bradycardia: A case report. SRIMEDJ [Internet]. 2022 Oct. 19 [cited 2024 Jul. 25];37(5):437-41. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/254491



Original Articles